The New Antibody Drugs at a Glance
If your myasthenia affects only your eyes, these newer antibody drugs are usually not your first step. The newer drugs are approved to treat myasthenia that has spread beyond the eyes, not eye-only disease1. When only the eye muscles are weak, doctors usually start with older, simpler treatments first2. A specialist helps you decide what fits, and this page explains the drugs so you can ask good questions.
Ocular myasthenia gravis is weakness of the eye muscles that causes a drooping eyelid (ptosis) and double vision, and the double vision goes away when either eye is closed2. Myasthenia gravis is an autoimmune disease, meaning the body's own immune system makes antibodies that block the signal between nerve and muscle3. That is why treatments aimed at the immune system, including these antibody drugs, are part of the picture.
This page is for adults whose myasthenia symptoms are, for now, only in the eyes and who are weighing what comes next. Many people who start with eye-only symptoms later develop generalized myasthenia that affects other muscles, so ongoing monitoring matters2. Nothing here is a diagnosis or a prescription; it is background for the plan you build with your own clinician.
What the New Antibody Drugs Are
FcRn blockers, such as efgartigimod (brand name Vyvgart), are laboratory-made antibody fragments that bind a protein called the neonatal Fc receptor and lower the level of circulating IgG antibodies, including the harmful ones that drive myasthenia1. By reducing those antibodies for a period of weeks, they aim to ease muscle weakness.
Complement inhibitors, such as ravulizumab (brand name Ultomiris) and eculizumab, work in a different way: they block a part of the immune system called complement, specifically the protein C5, to reduce damage at the nerve-muscle junction4. Eculizumab, ravulizumab and efgartigimod are examples of these newer targeted antibody drugs used for generalized myasthenia gravis2.
Older treatments either boost the nerve signal or broadly quiet the immune system. Pyridostigmine helps with the muscle-weakness symptoms, and steroids and other immune-suppressing medicines reduce antibody activity over the longer term2. The newer antibody drugs are more targeted, but that precision comes with its own risks and a much higher cost of monitoring, covered below.
How These Drugs Are Given
Unlike pyridostigmine, these drugs are not tablets you take at home on your own. Efgartigimod is given as an infusion into a vein over about one hour, once a week for four weeks, with later treatment cycles based on how you are doing and given no sooner than 28 days after the last dose1. Ravulizumab is given as an infusion into a vein, starting with a weight-based loading dose and then maintenance doses every 8 weeks4.
The rhythm of treatment differs by drug and is set by the prescriber, not chosen at home. Efgartigimod is repeated in cycles, and the next cycle is decided by clinical evaluation rather than on a fixed lifelong schedule1. Because the schedules and settings are specific, these drugs are managed in a clinic that treats myasthenia.
Preparation before the first dose is a safety step, not a formality. Because efgartigimod causes a temporary drop in IgG antibody levels, your clinician reviews whether you need any age-appropriate vaccines before a new treatment cycle1. Because complement inhibitors raise the risk of serious meningococcal infection, meningococcal vaccination covering serogroups A, C, W, Y and B is required at least 2 weeks before the first dose of ravulizumab4.
Side Effects to Know About
Most side effects are infections or general symptoms rather than something dramatic. In the studies of efgartigimod for generalized myasthenia, the most common side effects were respiratory tract infections in about 33 of every 100 people, headache in about 32 of every 100, and urinary tract infections in about 10 of every 1001. For ravulizumab, the most common side effects reported were diarrhea and upper respiratory tract infections, each in at least 10 of every 100 people4.
The most important serious risk is specific to the complement inhibitors. Ravulizumab carries a boxed warning that it increases the risk of serious, and sometimes fatal, meningococcal infection, which is why it is available only through a restricted safety program and why vaccination beforehand is required4. FcRn blockers such as efgartigimod can lower white blood cell counts and raise the chance of infection as well1.
Because these are given by infusion, reactions during or after treatment are possible. Serious allergic reactions, including anaphylaxis and low blood pressure leading to fainting, have been reported with efgartigimod1. Your infusion team watches for these and treats them, which is one reason the drugs are given in a monitored setting.
Who Should Be Cautious or Wait
Timing matters when your defenses against infection are being changed. A complement inhibitor should not be started until meningococcal vaccination is up to date, because the drug increases the risk of serious meningococcal infection4. Because efgartigimod lowers protective antibody levels and can reduce white blood cells, an active infection is a reason to be cautious about treatment1.
This is the central caution for readers of this page. Efgartigimod is approved for generalized myasthenia gravis in adults1. Ravulizumab is approved for adults with anti-acetylcholine-receptor antibody positive generalized myasthenia gravis4. Because neither approval covers disease limited to the eyes, using these drugs for eye-only myasthenia is off-label. Off-label use can still be reasonable in specific situations, but it is a shared decision made with a specialist, not a default.
Some situations call for extra discussion before starting. If you are pregnant, planning pregnancy, breastfeeding, or living with another serious illness, tell your clinician, because it can change whether and when one of these drugs fits. These drugs act on the immune system, so decisions about them are individualized rather than one-size-fits-all2.
Risks, Benefits, and a Realistic Outlook
The trials that led to approval of these antibody drugs enrolled people with generalized myasthenia gravis, not people whose disease was limited to the eyes1. In those generalized-MG studies the drugs improved muscle strength, which is the basis for their FDA approval. For your eyes-only situation, that evidence is encouraging background rather than direct proof.
Honesty about the gap matters here. Because the approval studies were done in generalized myasthenia, there is no large-trial evidence that these antibody drugs help when symptoms are limited to the eyes4. Any use in eye-only disease rests on a clinician's judgment about your specific case, weighed against the drug's known risks.
Myasthenia gravis is usually a long-term condition rather than something cured in one course of treatment. Because eye-only myasthenia can later spread to other muscles, the goal of care is to control symptoms and monitor for change over time, guided by a specialist2. Outcomes vary from person to person, and no medicine can promise a particular result for any one individual.
When to Call Your Doctor
Most eye symptoms are not emergencies, but a few changes are. Shortness of breath or difficulty swallowing are serious symptoms of myasthenia gravis, can be life-threatening, and need immediate medical attention2. When myasthenia weakens the breathing muscles it can cause a life-threatening emergency called a myasthenic crisis3. If these happen, get emergency help right away; the good news is that this is uncommon and treatable when caught early.
Infection warning signs deserve prompt attention, especially on a complement inhibitor. Because meningococcal infection can become rapidly life-threatening, a high fever, severe headache, stiff neck, or confusion during complement-inhibitor treatment needs urgent medical care4. Call the same day for a new fever or worsening infection while on any of these drugs.
Knowing who owns your care helps you get the right help fast. Myasthenia gravis is diagnosed and treated by neurologists and neuro-ophthalmologists, who also decide whether a newer antibody drug is appropriate2. Keep your routine follow-up visits so changes are caught early and your plan stays current.
Common Questions About These Drugs
No. Efgartigimod, an FcRn blocker, is approved for generalized myasthenia gravis in adults1. Ravulizumab, a complement inhibitor, is approved for adults with anti-acetylcholine-receptor antibody positive generalized myasthenia gravis4. Neither is approved for disease limited to the eyes. If your symptoms are only in your eyes, using one of these drugs would be an off-label decision made with a specialist who knows your full history. Standard first treatments for eye-only disease are usually tried before considering them.
For eye-only myasthenia, pyridostigmine helps the muscle-weakness symptoms, and steroids or other immune-suppressing medicines may be added when symptoms need more control2. These are usually tried first because they have a long track record. If they do not control your symptoms, your specialist can discuss what to consider next for your situation.
They target different parts of the immune system. FcRn blockers lower the level of harmful IgG antibodies1. Complement inhibitors instead block the complement protein C5 to reduce damage at the nerve-muscle junction4. Both are given by infusion, but they differ in schedule, monitoring, and their specific risks, which is part of what your specialist weighs.
Often, yes. Meningococcal vaccination is required at least 2 weeks before the first dose of a complement inhibitor because the drug raises the risk of serious meningococcal infection4. For an FcRn blocker, your clinician reviews whether you need other vaccines because the drug temporarily lowers your antibody levels1.
No. Efgartigimod is given as an infusion into a vein in a clinic, once weekly for four weeks and then in later cycles1. Ravulizumab is also given by vein, with a loading dose and then maintenance doses every 8 weeks4. Because they need a monitored setting, they are not something you start or adjust on your own.
Most are infections or general symptoms. With efgartigimod, respiratory infections, headache, and urinary tract infections were the most common side effects in studies1. With ravulizumab, diarrhea and upper respiratory infections were most common4. The more serious concern, especially with complement inhibitors, is a higher risk of serious infection, which is why vaccination and monitoring matter.
More Questions Patients Ask
The eye symptoms themselves are not dangerous, but the disease can spread. Eye-only myasthenia can develop into generalized disease over time, and if breathing or swallowing muscles weaken, that is a life-threatening emergency needing immediate care2. This is why regular follow-up matters even when your symptoms feel limited to your eyes, so any change is caught and treated early.
This is a specialist decision, made with you. Neurologists and neuro-ophthalmologists diagnose and treat myasthenia gravis and decide whether a newer antibody drug is appropriate2. They weigh how well your current treatment is working, your antibody test results, your infection risk, and your preferences. It is a shared decision, not something started automatically.
Not directly. The large trials behind these drugs enrolled people with generalized myasthenia, so there is no large-trial proof that they help when symptoms are limited to the eyes1. Reports of use in eye-only disease exist, but they do not replace a trial. Your specialist can explain how that uncertainty applies to your own case.
- Is my myasthenia limited to my eyes, and how will we know if it is spreading?
- What are my first-line options, and have we given them a fair trial?
- If we consider a newer antibody drug, would it be off-label for my situation, and why?
- Which vaccines do I need before starting, and how long do I wait afterward?
- What side effects and warning signs should I watch for at home?
- Who do I call, and how fast, if my breathing or swallowing changes?
- DailyMed (U.S. FDA label), argenx (2025). VYVGART (efgartigimod alfa-fcab) Prescribing Information.
- North American Neuro-Ophthalmology Society (NANOS) (2023). Myasthenia Gravis (Patient Information).
- American Academy of Ophthalmology (EyeSmart) (2023). What Is Myasthenia Gravis?.
- DailyMed (U.S. FDA label), Alexion / AstraZeneca (2024). ULTOMIRIS (ravulizumab-cwvz) Prescribing Information.